Amarin (AMRN)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.11%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 81 - 100 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Applications for Vascepa; Reiterate Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Optimism in European Opportunity, While Generics Enter the Fray; PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Following Affirmation of Patent Invalidation, Focus is on the EU Vascepa Opportunity
Provider: Piper Sandler
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Panel Affirms Ruling Invalidating Vascepa IP In The US; Focus Shifts To EU But Surprised Mgmt Not Looking To Cut Costs Now
Provider: Stifel Nicolaus Co., Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Patent Appeal Hearing Does Not Inspire Confidence
Provider: Oppenheimer & Co. Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Prospects for CAFC Reversal Dampened - Outperform Rating Remains Intact
Provider: Northland Capital Markets
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Color From Appeal Hearing Incrementally Negative For AMRN, In Our View; We Are Staying On The Sidelines
Provider: Stifel Nicolaus Co., Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Consultant Affirms Judges Were Tough, Remain HOLD Though US Now Priced Out...
Provider: Jefferies & Company
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Battle Didn''t Go as Planned but the War is Far from Over
Provider: Piper Sandler
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Federal Appeals Decision Expected as Soon 2020, Pushing Forward With European Impetus; PT Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A